Market Overview: The Global Nasal Polyposis Drugs Market is expanding rapidly, owing to advances in biologic medicines, minimally invasive surgical procedures, and personalized medicine approaches.

Patients with familial adenomatous polyposis have a nearly 100 percent risk of colorectal cancer. In this disease, the chemopreventive effects of nonsteroidal antiinflammatory drugs may be related ...

Colorectal cancer develops in about 80% of people with attenuated FAP. Signs and symptoms of familial adenomatous polyposis (FAP) People with classic FAP can start growing polyps in their colon as ...

Characterization of hereditary tumor risk in individuals with SDHA germline variants. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text ...

The adenomatous polyposis coli (APC) gene product is mutated in the vast majority of human colorectal cancers. APC negatively regulates the WNT pathway by aiding in the degradation of beta-catenin, ...

Biodexa receives a $3.0M CPRIT grant, totaling $20.0M for eRapa's Phase 3 program treating familial adenomatous polyposis. Biodexa Pharmaceuticals PLC has announced that its collaboration partner ...

Background: The prevalence of duodenal carcinoma is much higher in familial adenomatous polyposis (FAP) than in the background population, and duodenal adenomatosis is found in most polyposis patients ...

amc.uva.nl Objective Serrated polyposis syndrome (SPS) is accompanied by an increased risk of colorectal cancer (CRC). Patients fulfilling the clinical criteria, as defined by the WHO, have a wide ...

Familial adenomatous polyposis is an inherited condition that significantly increases the risk for colon cancer. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TPST-1495 ...

Tezepelumab was generally well tolerated in patients with severe nasal polyposis and demonstrated a safety profile consistent with its current indication for severe asthma. The most frequently ...

Scientists have discovered that a bacterial toxin, colibactin, may contribute to the rising rates of bowel cancer in young ...

Background: In patients with juvenile polyposis syndrome (JPS) the frequency of large genomic deletions in the SMAD4 and BMPR1A genes was unknown. Methods: Mutation and phenotype analysis was used in ...